This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Carson, J. P. Articles by Christman, M. F. Search for Related Content PubMed PubMed Citation Articles by Carson, J. P. Articles by Christman, M. F.

Pharmacogenomic Identification of Targets for Adjuvant Therapy with the Topoisomerase Poison Camptothecin

Department of Genetics and Genomics, Boston University School of Medicine, Boston, Massachusetts

The response of tumor cells to the unusual form of DNA damage caused by topoisomerase poisons such as camptothecin (CPT) is poorly understood, and knowledge regarding which drugs can be effectively combined with CPT is lacking. To better understand the response of tumor cells to CPT and to identify potential targets for adjuvant therapy, we examined global changes in mRNA abundance in HeLa cells after CPT treatment using Affymetrix U133A GeneChips, which include all annotated human genes (22,283 probe sets). Statistical analysis of the data using a Bayesian/Cyber t test and a modified Benjamini and Hochberg correction for multiple hypotheses testing identified 188 probe sets that are induced and 495 that are repressed 8 h after CPT treatment at a False Discovery Rate of <0.05 and a minimum 3-fold change. This pharmacogenomic approach led us to identify two pathways that are CPT induced: (a) the epidermal growth factor receptor; and (b) nuclear factor-B-regulated antiapoptotic factors. Experiments using HeLa cells in our lab and prior animal model studies performed elsewhere confirm that inhibitors of these respective pathways super-additively enhance CPT’s cytotoxicity, suggesting their potential as targets for adjuvant therapy with CPT.

This article has been cited by other articles:

				S. E. Mortimer, D. Xu, D. McGrew, N. Hamaguchi, H. C. Lim, S. J. Bowne, S. P. Daiger, and L. Hedstrom IMP Dehydrogenase Type 1 Associates with Polyribosomes Translating Rhodopsin mRNA J. Biol. Chem., December 26, 2008; 283(52): 36354 - 36360. [Abstract] [Full Text] [PDF]

				Y. Gong, J. Yue, X. Wu, X. Wang, J. Wen, L. Lu, X. Peng, B. Qiang, and J. Yuan NSPc1 is a cell growth regulator that acts as a transcriptional repressor of p21Waf1/Cip1 via the RARE element Nucleic Acids Res., December 4, 2006; 34(21): 6158 - 6169. [Abstract] [Full Text] [PDF]

				S. A. Byers, J. P. Price, J. J. Cooper, Q. Li, and D. H. Price HEXIM2, a HEXIM1-related Protein, Regulates Positive Transcription Elongation Factor b through Association with 7SK J. Biol. Chem., April 22, 2005; 280(16): 16360 - 16367. [Abstract] [Full Text] [PDF]